deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT vs. androgen deprivation therapy (ADT) 2 certainty unassessablestatistically conclusive-34%
apalutamide plus ADT vs. androgen deprivation therapy (ADT) 1 certainty unassessablestatistically conclusive-30%
docetaxel plus ADT vs. androgen deprivation therapy (ADT) 4 certainty unassessablestatistically conclusive-22%
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 certainty unassessable-31%
versus docetaxel plus ADT
abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT 1 certainty unassessablestatistically conclusive-23%
darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT 1 certainty unassessablestatistically conclusive-29%